Affinium Pharmaceuticals, Ltd. Announces the Initiation of a Phase I ClinicalTrial Using an Oral Formulation of AFN-1252
Dr. Barry Hafkin, Chief Medical Officer of Affinium Pharmaceuticals, noted, "We have previously documented good oral bioavailability and excellent tolerability of the drug candidate in two previous clinical studies using simple oral formulations, and we are very pleased to move a newly developed oral formulation that we expect will optimize the pharmacokinetic profile of AFN-1252. We anticipate that the trial will be completed in the third quarter of this year, and that AFN-1252 will continue to demonstrate the excellent tolerability and safety seen in previous studies."
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.